2026-03-02T12:03:53-06:00 2025-06-30 860683059 BEACHFLEISCHMAN PLLC 1985 E RIVER ROAD SUITE 201 TUCSON AZ 85718 990 2024-07-01 201991334 CRITICAL PATH INSTITUTE CRIT 5205473440 1840 E RIVER ROAD 100 TUCSON AZ 85718 KRISTEN SWINGLE PRESIDENT & COO 5205473440 2026-02-18 1 1 KELLY L MELTZER CPA P00633511 5203214600 2026-02-18 2024 2025-03-06 01:10:19Z DR KLAUS ROMERO 1840 E RIVER ROAD 100 TUCSON AZ 85718 52783745 0 X C-PATH.ORG X 2004 AZ INTERNATIONAL COLLABORATIONS AND NOVEL TOOLS TO ENABLE FASTER DEVELOPMENT OF SAFE MEDICAL PRODUCTS 16 16 176 16 0 0 28598217 33561505 13063062 12287265 949583 934975 0 0 42610862 46783745 5059784 5186032 0 0 23557206 25569910 0 0 0 9727627 9476418 38344617 40232360 4266245 6551385 31286582 38361666 11754467 12096569 19532115 26265097 X THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. 0 0 6720599 CRITICAL PATH FOR RARE NEURODEGENERATIVE DISEASES (CP-RND) - SEE SCHEDULE O 6059856 1319385 RARE DISEASE CURES ACCELERATOR-DATA AND ANALYTICS PLATFORM (RDCA-DAP) - SEE SCHEDULE O 2886756 1612597 CRITICAL PATH INSTITUTE'S TRANSLATIONAL THERAPEUTICS ACCELERATOR (TRXA) - SEE SCHEDULE O 15684004 2254049 12287265 CRITICAL PATH INSTITUTE ALSO EXECUTES OTHER PROJECTS AND CONSORTIA IN AREAS INCLUDING THERAPEUTICS FOR THE ATAXIAS, POLYCYSTIC KIDNEY DISORDER, ALZHEIMER'S DISEASE, PARKINSON'S, TB, SICKLE CELL DISEASE, TYPE 1 DIABETES, DUCHENNE MUSCULAR DYSTROPHY, ALPHA-1 ANTITRYPSIN DEFICIENCY, LYSOSOMAL DISEASES, MODEL INFORMED DRUG DEVELOPMENT, PATIENT-REPORTED OUTCOME, ELECTRONIC CLINICAL OUTCOME ASSESSMENT, RARE DISEASE CLINICAL OUTCOME ASSESSMENT, TRANSPLANT THERAPEUTICS, PREDICTIVE SAFETY TESTING, PEDIATRICS, AND OTHERS. 15684004 2254049 12287265 31351215 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0 1 0 0 1 176 1 0 1 NL 0 0 0 0 0 0 0 0 0 0 X 16 16 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X KRISTEN SWINGLE 5205473440 1840 E RIVER ROAD 100 TUCSON AZ 85718 MS BONNIE ALLIN BOARD MEMBER 1.00 X 0 0 0 MS MARA G ASPINALL BOARD MEMBER 1.00 X 0 0 0 MR PETER BARTON HUTT BOARD MEMBER 1.00 X 0 0 0 DR KAREN BERNSTEIN BOARD MEMBER 1.00 X 0 0 0 MR LOUIS BRETON BOARD MEMBER 1.00 X 0 0 0 DR TIMOTHY R FRANSON BOARD MEMBER 1.00 X 0 0 0 MS KAY HOLCOMBE BOARD MEMBER 1.00 X 0 0 0 MR SHAUN A KIRKPATRICK BOARD MEMBER 1.00 X 0 0 0 MR ALAN G LEVIN BOARD MEMBER 1.00 X 0 0 0 MR JAMES W NEWMAN BOARD MEMBER 1.00 X 0 0 0 DR TOMAS SALMONSON BOARD MEMBER 1.00 X 0 0 0 MR M WAINWRIGHT FISHBURN JR CHAIRMAN 1.00 X X 0 0 0 MR JEFFERY JACOB VICE CHAIRMAN 1.00 X X 0 0 0 DR KLAUS ROMERO CEO 40.00 X 465393 0 53687 MS KRISTEN SWINGLE PRESIDENT & COO 40.00 X 382404 0 57742 MR KEVIN PERKINS CHIEF FINANCIAL OFFICER & TREASURER 40.00 X 279156 0 45481 MR PAUL EDMEIER CHIEF FINANCIAL OFFICER & TREASURER 40.00 X 0 0 0 MR LEWIS BARBIERI CORPORATE SECRETARY 40.00 X 150328 0 26765 MR RICHARD LIWSKI CHIEF TECHNOLOGY OFFICER 40.00 X 267416 0 38055 MR COLLIN HOVINGA VP PROGRAMS 40.00 X 273459 0 22337 DR CHERYL COON VP PROGRAMS 40.00 X 322075 0 42056 DR MARCO SCHITO EXECUTIVE DIRECTOR 40.00 X 261008 0 32936 DR SUDHIR SIVAKUMARAN EXECUTIVE DIRECTOR 40.00 X 256179 0 3315 DR MAAIKE EVERTS EXECUTIVE DIRECTOR 40.00 X 257993 0 38055 DR DIANE STEPHENSON EXECUTIVE DIRECTOR 40.00 X 260883 0 36587 MS SONYA EREMENCO EXECUTIVE DIRECTOR 40.00 X 242607 0 37784 DR SHU CHIN MA VP PROGRAMS 40.00 X 255657 0 19574 MR YI ZHANG SENIOR DIRECTOR 40.00 X 197565 0 49372 3872123 0 503746 81 0 1 0 ARIDHIA INFORMATICS LIMITED 163 BATH STREET GLASGOW UK IT SERVICES 1420719 AMAZON WEB SERVICES INC PO BOX 81207 SEATTLE WA 98124 IT SERVICES 436866 LOTOS NILE PO BOX 90245 NASHVILLE TN 37209 PUBLIC RELATIONS 384258 TRIPLE POINTE HOLDINGS LLC 378 PEAKHAM ROAD SUDBURY MA 01776 CONSULTING 247458 ROCHE DIAGNOSTICS OPERATIONS INC 9115 HAGUE ROAD INDIANAPOLIS IN 46250 RESEARCH SUPPORT 245000 11 20724703 12836802 33561505 RESEARCH SUPPORT FEES 541700 11914937 11914937 OTHER REVENUE 900099 372328 372328 12287265 934975 934975 6000000 6000000 0 46783745 12287265 0 934975 3759058 3759058 1426974 1426974 2342583 1261059 1081524 18554068 15147423 3406645 1252317 1024794 227523 2008857 1472489 536368 1412085 1113444 298641 55396 55396 90175 90175 60000 60000 2464764 2180010 284754 483137 37250 445887 431331 60071 371260 2859969 1967820 892149 521675 380090 141585 878809 554138 324671 1351528 935076 416452 15442 2002 13440 192747 192747 DUES AND SUBSCRIPTIONS 63995 29160 34835 MISCELLANEOUS 7450 357 7093 40232360 31351215 8881145 0 1348508 1582265 23250388 23177979 2953014 3222404 1763675 846693 140256 112606 97242 95374 17310 1868 0 7939830 1813431 1478021 31286582 38361666 3269884 3072100 6779327 7751209 1705256 1273260 11754467 12096569 X 14406381 16507758 5125734 9757339 19532115 26265097 31286582 38361666 6551385 181597 0 X 0 1 X 1 1 1 X 17810315 23061454 23557036 28598217 33561505 126588527 17810315 23061454 23557036 28598217 33561505 126588527 11761589 114826938 5817 6633 403834 949583 934975 2300842 128889369 51375733 0.89090 0.92430 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 60000 60000 40172360 40232360 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 60000 60000 120000 250000 250000 250000 250000 1000000 1500000 97242 95374 1868 1868 OPERATING LEASE OBLIGATIONS 1273260 1273260 X PART X, LINE 2: FINANCIAL STATEMENT ASC 740 FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION UNDER INTERNAL REVENUE CODE SECTION 509(A)(1). INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME. 1 EAST ASIA (AUSTRALIA, CHINA) 0 0 PROGRAM SERVICES/BUSINESS SERVICES RESEARCH SUPPORT 10000 EUROPE (BELGIUM, SWEDEN, FRANCE, FINLAND) 0 0 PROGRAM SERVICES/BUSINESS SERVICES CLINICAL RESEARCH, IT SERVICES, DUES, CONSULTING, RESEARCH SUPPORT 251153 EUROPE (UNITED KINGDOM) 0 0 PROGRAM SERVICES/BUSINESS SERVICES CONSULTING, REGULATORY FEES, DUES, EVENT HOSTING 1236633 EUROPE (NETHERLANDS) 1 10 PROGRAM SERVICES/BUSINESS SERVICES PAYROLL SERVICES, OUTSIDE PROFESSIONAL 1600639 NORTH AMERICA (CANADA) 0 0 PROGRAM SERVICES/BUSINESS SERVICES CONSULTING 61785 EAST ASIA (AUSTRALIA, CHINA) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION SUBAWARD 600978 EUROPE (UNITED KINGDOM) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION SUBAWARD 825996 1 10 0 0 1 10 4587184 0 4587184 EUROPE (UNITED KINGDOM) SUBAWARD 670055 WIRE TRANSFER 0 EUROPE (UNITED KINGDOM) SUBAWARD 155941 WIRE TRANSFER 0 EAST ASIA (AUSTRALIA, CHINA) SUBAWARD 68978 WIRE TRANSFER 0 EAST ASIA (AUSTRALIA, CHINA) SUBAWARD 532000 WIRE TRANSFER 0 3 1 0 1 1 0 0 0 PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. 1 NATIONAL ORGANIZATION FOR RARE DISORDERS 1900 CROWN COLONY DRIVE SUITE 310 QUINCY MA 02169 133223946 501(C)(3) 1319385 0 SUBAWARD NORTHWESTERN UNIVERSITY 633 CLARK STREET ROOM G-547 EVANSTON IL 60208 362167817 501(C)(3) 381946 0 SUBAWARD UNIVERSITY OF CALIFORNIA 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 501(C)(3) 347500 0 SUBAWARD SEATTLE CHILDREN'S HOSPITAL PO BOX 5371 M/S RC-507 SEATTLE WA 98145 910564748 501(C)(3) 234728 0 SUBAWARD WAKE FOREST UNIVERSITY PO BOX 604096 CHARLOTTE NC 28260 223849199 501(C)(3) 215717 0 SUBAWARD YALE UNIVERSITY 150 MUNSON STREET 3RD FLOOR NEW HAVEN CT 06520 060646973 501(C)(3) 172778 0 SUBAWARD UNIVERSITY OF PITTSBURGH 500 ROSS STREET 154-0455 LOCK-BOX 371220 PITTSBURGH PA 15262 250965591 501(C)(3) 145000 0 SUBAWARD WASHINGTON UNIVERSITY 7425 FORSYTH BOULEVARD MSC 1299-414-355 ST LOUIS MO 63102 430653611 501(C)(3) 140000 0 SUBAWARD UNIVERSITY HOSPITAL CLEVELAND MEDICAL CTR 11100 EUCLID AVENUE CLEVELAND OH 44106 341567805 501(C)(3) 127093 0 SUBAWARD BIOAGILYTIX LABS 2300 ENGLERT DRIVE DURHAM NC 27713 262395593 111767 0 SUBAWARD HMH HOSPITALS CORP 111 IDEATION WAY NUTLEY NJ 07110 221487576 501(C)(3) 109798 0 SUBAWARD UNIVERSITY OF ARIZONA PO BOX 41867 TUCSON AZ 85717 742652689 STATE OF ARIZONA 102500 0 SUBAWARD BANNER HEALTH 2901 N CENTRAL AVENUE SUITE 160 PHOENIX AZ 85012 450233470 501(C)(3) 97488 0 SUBAWARD PENNSYLVANIA STATE UNIVERSITY 500 UNIVERSITY DRIVE HERSHEY PA 17033 246000376 STATE OF PENNSYLVANI 92500 0 SUBAWARD ILLUMINA 5200 ILLUMINA WAY SAN DIEGO CA 92122 330804655 77336 0 SUBAWARD UNIVERSITY OF TEXAS 110 INNER CAMPUS DRIVE STOP KI5300 AUSTIN TX 78712 746000203 STATE OF TEXAS 60000 0 SUBAWARD XCURES INC 1901 HARRISON STREET SUITE 1100 OAKLAND CA 94612 824349790 23000 0 SUBAWARD 14 3 PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. X X X X X 0 0 0 0 0 0 0 1 0 DR KLAUS ROMERO CEO 431193 0 34200 0 0 0 34736 0 18951 0 519080 0 0 0 MS KRISTEN SWINGLE PRESIDENT & COO 357114 0 25290 0 0 0 27721 0 30021 0 440146 0 0 0 DR CHERYL COON VP PROGRAMS 289127 0 32948 0 0 0 23393 0 18663 0 364131 0 0 0 MR KEVIN PERKINS CHIEF FINANCIAL OFFICER & TREASURER 255156 0 24000 0 0 0 21128 0 24353 0 324637 0 0 0 MR RICHARD LIWSKI CHIEF TECHNOLOGY OFFICER 243851 0 23565 0 0 0 18742 0 19313 0 305471 0 0 0 DR DIANE STEPHENSON EXECUTIVE DIRECTOR 238656 0 22227 0 0 0 17444 0 19143 0 297470 0 0 0 DR MAAIKE EVERTS EXECUTIVE DIRECTOR 234428 0 23565 0 0 0 18742 0 19313 0 296048 0 0 0 MR COLLIN HOVINGA VP PROGRAMS 253459 0 20000 0 0 0 20046 0 2291 0 295796 0 0 0 DR MARCO SCHITO EXECUTIVE DIRECTOR 256179 0 4829 0 0 0 15740 0 17196 0 293944 0 0 0 MS SONYA EREMENCO EXECUTIVE DIRECTOR 220359 0 22248 0 0 0 18345 0 19439 0 280391 0 0 0 DR SHU CHIN MA VP PROGRAMS 241207 0 14450 0 0 0 18592 0 982 0 275231 0 0 0 DR SUDHIR SIVAKUMARAN EXECUTIVE DIRECTOR 256179 0 0 0 0 0 2198 0 1117 0 259494 0 0 0 MR YI ZHANG SENIOR DIRECTOR 194259 0 3306 0 0 0 15960 0 33412 0 246937 0 0 0 MR LEWIS BARBIERI CORPORATE SECRETARY 146198 0 4130 0 0 0 11891 0 14874 0 177093 0 0 0 PART I, LINE 7 CRITICAL PATH AWARDS VARIABLE COMPENSATION BASED ON PERFORMANCE AND WITH GUIDANCE FROM THE COMPENSATION COMMITTEE. KYLA OETTING FAMILY RELATIONSHIP - STEP-DAUGHTER OF LOUIS BRETON, BOARD MEMBER 49924 EMPLOYMENTMS. OETTING IS EMPLOYED BY CRITICAL PATH INSTITUTE AS A PROGRAM COORDINATOR. 0 FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICES CP-RND WAS FOUNDED IN SEPTEMBER 2022 PURSUANT TO THE ACT FOR ALS IN ORDER TO DEVELOP COLLABORATIONS THAT ADVANCE TREATMENTS TO IMPROVE THE LIVES OF THOSE AFFECTED BY RARE NEURODEGENERATIVE DISEASES, INCLUDING ALS. IN THE FIRST TWO YEARS OF THE PROJECT, CP-RND HAS ACHIEVED IMPORTANT MILESTONES REGARDING THE FOCUS ON PATIENT-FOCUSED DRUG DEVELOPMENT, DATA COLLECTION AND AGGREGATION, AND DRUG DEVELOPMENT TOOL SOLUTIONS TO ADDRESS THE GAPS IN DRUG DEVELOPMENT FOR RARE NEURODEGENERATIVE DISEASES. CP-RND ALSO ESTABLISHED A PWLE WORKING GROUP IN COORDINATION WITH ACCELERATING MEDICINE PARTNERSHIP (AMP IN FNIH) TO GIVE AND RECEIVE FEEDBACK ON ALS-RELATED PROJECTS. CP-RND HAS INITIATED WORKING GROUPS FOCUSED ON CLINICAL OUTCOME ASSESSMENTS (COAS), DIGITAL HEALTH TECHNOLOGY TOOLS AND DATA IN ORDER COLLABORATE WITH KEY OPINION LEADERS TO MORE CLEARLY IDENTIFY AND ADDRESS GAPS IN DRUG DEVELOPMENT. UPON RECOMMENDATION BY THE FDA, CP-RND COMPLETED A THOROUGH EVALUATION OF THE COMMON COAS USED IN ALS CLINICAL TRIALS AGAINST THE FDA'S ROADMAP FOR DEVELOPING PATIENT-FOCUSED OUTCOME MEASURES AND MADE RECOMMENDATIONS ON METHODS TO IMPROVE OR DEVELOP COAS FOR KEY CONCEPTS IMPORTANT TO PWLE WITH ALS. CP-RND HAS RESEARCHED OVER 70 LARGE DATABASES, WITH A PRIORITY LISTING CREATED AND SHARED WITH NIH, FNIH AND FDA. CP-RND, IN PARTNERSHIP WITH RDCA-DAP, IS WORKING TO CREATE AN ALS DATA KNOWLEDGE PORTAL CONTAINING PRIORITIZED DATASETS THAT CAN BE STANDARDIZED AND USED BY STAKEHOLDERS TO ADVANCE RESEARCH IN ALS INCLUDING THE DEVELOPMENT OF DRUG DEVELOPMENT TOOLS. OF THE PRIORITY LISTING CREATED, THREE DATA SETS HAVE BEEN RECEIVED AND ARE IN VARIOUS STAGES OF CURATION AND AGGREGATION. PROGRESS FOR DATA DICTIONARY COLLECTION AND DATA SHARE AGREEMENTS REMAIN ONGOING WITH THE REMAINING DATA SETS IDENTIFIED. FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICES RDCA-DAP IS AN FDA-FUNDED INITIATIVE THAT PROVIDES A CENTRALIZED AND STANDARDIZED INFRASTRUCTURE TO SUPPORT AND ACCELERATE RARE DISEASE CHARACTERIZATION WITH THE GOAL OF ACCELERATING THERAPY DEVELOPMENT. THE RDCA-DAP EFFORT STARTED IN 2019 AND LAUNCHED THE PUBLIC INTERFACE OF THE PLATFORM IN SEPTEMBER 2021. TO DATE, THE PLATFORM HOSTS OVER 80 RARE DISEASE DATA SETS REPRESENTING OVER 41 DISEASE STATES. THERE ARE NOW 642 PLATFORM USERS AND 43 ACTIVE WORKSPACES, WHERE USERS ACTIVELY LEVERAGE THE RDCA-DAP DATABASE TO INFORM RARE DISEASE RESEARCH AND DRUG DEVELOPMENT ACTIVITIES. ACTIVE AGREEMENTS CURRENTLY INCLUDE 42 DATA CONTRIBUTION AGREEMENTS, 8 NORD DATA CONTRIBUTION COVERSHEETS, 3 CORDS REGISTRY DATA CONTRIBUTION COVERSHEETS, AND 34 TASK FORCE AGREEMENTS. RDCA-DAP LEVERAGED FRIEDREICH'S ATAXIA DATABASE TO DEVELOP A CLINICAL TRIAL SIMULATION TOOL TO INFORM TRIAL DESIGN IN FA. THE TOOL ENTERED REGULATORY SUBMISSION TO THE OFFICE OF CLINICAL PHARMACOLOGY IN SEPTEMBER 2024. THREE TASK FORCES STRUCTURED AS SMALL SCALE PUBLIC PRIVATE PARTNERSHIPS WERE LAUNCHED IN 2023 AND 2024 TO LEVERAGE THE DATABASE AND ADVANCE DRUG DEVELOPMENT SOLUTIONS. THE PROGRESSIVE SUPRANUCLEAR PALSY AND LIMB-GIRDLE MUSCULAR DYSTROPHY TASK FORCES ARE ADVANCING DISEASE PROGRESSION MODELING TO INFORM TRIAL DESIGN, AND THE RARE MITOCHONDRIAL DISEASES TASK FORCE IS FOCUSED ON DATA AGGREGATION TO DEVELOP RECOMMENDATIONS AIMED AT ENHANCING REAL WORLD DATA COLLECTION AND BEST PRACTICES. 2023 MARKED THE RELEASE OF CRITICAL PATH ONTOLOGY (CPONT) APPLICATION, WHICH FACILITATES MAPPING AND LINKING BETWEEN DIFFERENT STANDARDIZED DATA VOCABULARIES. IN ADDITION, A PUBLICATION WAS PUBLISHED IN THE JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (BARRETT JS ET AL., 2023). LASTLY, THE PROGRAM MADE A SIGNIFICANT IMPACT ON PROFESSIONAL DEVELOPMENT IN 2024, WITH EIGHT WEBINARS HELD AS PART OF ITS PROFESSIONAL DEVELOPMENT SERIES, REACHING 772 REGISTRANTS AND 37,344 ATTENDEES. FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICES CRITICAL PATH INSTITUTE'S TRANSLATIONAL THERAPEUTICS ACCELERATOR (TRXA), LAUNCHED IN 2022, IS DESIGNED TO ASSIST ACADEMIC INVESTIGATORS IN OVERCOMING THE DRUG DEVELOPMENT "VALLEY OF DEATH" BY PROVIDING STRATEGIC FUNDING AND MENTORSHIP. THROUGH ITS BRIDGING RESEARCH AND INNOVATION IN DRUG DEVELOPMENT GRANTS (BRIDGE) PROGRAM, INVESTIGATORS ARE SUPPORTED BY TRXA IN DEFINING AND IMPLEMENTING EFFECTIVE PATHWAYS FOR ADVANCING PROMISING THERAPEUTIC CANDIDATES FROM THE LABORATORY TOWARD CLINICAL EVALUATION. IN 2024, TRXA SUPPORTED FOUR (4) DRUG DEVELOPMENT PROJECTS WITH A TOTAL OF $1,612,597 IN GRANT FUNDING. IN ADDITION TO FUNDING, GRANTEES RECEIVED THE FOLLOWING: - STRATEGIC AND TACTICAL EXPERTISE IN DRUG DISCOVERY AND DEVELOPMENT, INCLUDING CONSIDERATIONS IN REGULATORY SCIENCE AND PRECLINICAL STRATEGY. - RESOURCES AND HANDS-ON GUIDANCE TO BUILD COMPREHENSIVE DATA PACKAGES THAT STRENGTHEN THE VALUE AND ATTRACTIVENESS OF THERAPEUTIC CANDIDATES FOR PARTNERSHIP WITH BIOTECHNOLOGY OR PHARMACEUTICAL COMPANIES. - SUPPORT IN ENGAGEMENT OF CONTRACT RESEARCH ORGANIZATIONS (CROS) TO CONDUCT KEY DISCOVERY-PHASE EXPERIMENTS AND VALIDATE ACADEMIC FINDINGS, ENSURING DATA ROBUSTNESS AND REPRODUCIBILITY. IN ADDITION, THROUGH ITS 2024 REQUEST FOR PROPOSALS, TRXA IDENTIFIED SEVEN (7) NEW PROJECTS FOR BRIDGE AWARDS, TOTALING $2.4 MILLION, TO BE FUNDED IN THE 2025 CALENDAR YEAR. FORM 990, PART VI, SECTION A, LINE 2 JEFF JACOB AND SHAUN KIRKPATRICK HAVE A BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S CFO, PRESIDENT/COO, CEO, THE BOARD AUDIT, FINANCE, AND RISK COMMITTEE, AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C ALL MEMBERS OF THE BOARD OF DIRECTORS AND ALL OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILL OUT A CONFLICT OF INTEREST FORM ANNUALLY. THE RESULTS ARE COMPILED AND REVIEWED BY THE BOARD'S AUDIT, FINANCE, AND RISK COMMITTEE. ANY ACTUAL OR PERCEIVED CONFLICTS THAT HAVE THE POTENTIAL TO BIAS ANY DISCUSSIONS OR DECISIONS BY THE BOARD ARE DISCUSSED BY THE BOARD. ANY DIRECTOR WITH A REAL OR POTENTIAL CONFLICT WILL RECUSE THEMSELVES FROM ANY DISCUSSION OR DECISION WHERE THE CONFLICT HAS A BEARING. FORM 990, PART VI, SECTION B, LINE 15 A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. PERIODICALLY, THE COMMITTEE REQUESTS A COMPENSATION ANALYSIS TO DETERMINE IF EMPLOYEE COMPENSATION HAS REMAINED WITHIN MARKET RANGE OR IF ADJUSTMENTS ARE REQUIRED. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS COMPENSATION COMMITTEE BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/COO. FORM 990, PART VI, SECTION C, LINE 19 ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. CRITICAL PATH INSTITUTE STICHTING 1083 HN AMSTERDAM AMSTERDAM NL EDUCATION AND RESEARCH IN EUROPE TO ACCELERATE DEVELOPMENT OF NEW THERAPIES NL 846214 546510 CRITICAL PATH INSTITUTE CRITICAL PATH INSTITUTE LTD 33 SIR JOHN ROGERSONS QUAY DUBLIN EI EDUCATION AND RESEARCH IN EUROPE TO ACCELERATE DEVELOPMENT OF NEW THERAPIES EI CRITICAL PATH INSTITUTE STICHTING C 1.00000 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0